Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-10-17EMA Authorised: Polivy (polatuzumab vedotin) — Roche Registration GmbH
The European Medicines Agency authorised Polivy (polatuzumab vedotin) from Roche Registration GmbH for a B-cell lymphoma indication.
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study of the monoclonal antibody IMT-009 in various advanced solid tumors and lymphomas, with t…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies [Phase 2]
This update reports a Phase 2 trial of loncastuximab tesirine for relapsed or refractory B-cell malignancies that is currently recruiting, i…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers [NA]
Memorial Sloan Kettering Cancer Center reports an ongoing trial evaluating a communication training intervention for clinicians treating lar…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS other · 2025-10-06Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large …
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2, Phase 3]
A Phase 2/3 clinical trial is evaluating the addition of selinexor to the Rituximab-Gemcitabine-Dexamethasone-Platinum regimen for relapsed/…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Bio-CAR-T BS Study
A clinical trial update indicates the Bio-CAR-T BS study is currently recruiting for diffuse large B-cell lymphoma, primary mediastinal B-ce…
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205] [Phase 2]
A Phase 2 master protocol evaluating SAR-444245 for relapsed or refractory B-cell lymphoma was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant [Phase 1]
Phase 1 trial evaluating Purinostat Mesylate for Injection in relapsed or refractory B cell–related tumors, including diffuse large B-cell l…
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
A Phase 2 trial of Selinexor (KPT-330) for relapsed or refractory diffuse large B-cell lymphoma is currently recruiting. No trial results ar…
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of rituximab, chemotherapy, and yttrium-90 ibritumomab tiuxetan in patients with newly diagnosed …
-
CLINICAL_TRIALS trial_result · 2025-09-30Clinical Trial Update: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib before and after stem cell transplantation in relapsed or refractory diffuse large B-cell lymphoma (activ…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) [Phase 3]
Phase 3 trial Pola-R-ICE vs R-ICE in second-line Diffuse Large B-Cell Lymphoma is currently active but not recruiting. The study evaluates a…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? [NA]
This clinical trial investigates whether trogocytosis can serve as a predictive biomarker for CAR-T cell response in patients with diffuse l…
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS [Phase 2]
Phase 2 trial update evaluating Brentuximab Vedotin with R-CHP in newly diagnosed EBV-positive diffuse large B-cell lymphoma, NOS; the study…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating epcoritamab in combination with standard platinum-based chemotherapy and autologous hematopoietic cell transplant…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy [Phase 2]
A Phase 2 clinical trial evaluating odronextamab for relapsed or refractory diffuse large B-cell lymphoma before and after CAR T-cell therap…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]
A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A clinical trial update for GNC-038, a tetra-specific antibody, in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in Phase 1/2, c…